A detailed history of Sonata Capital Group Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Sonata Capital Group Inc holds 1,824 shares of ABBV stock, worth $328,320. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,824
Previous 2,244 18.72%
Holding current value
$328,320
Previous $385,000 6.49%
% of portfolio
0.15%
Previous 0.2%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$163.84 - $199.33 $68,812 - $83,718
-420 Reduced 18.72%
1,824 $360,000
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $34,400 - $38,742
-250 Reduced 10.02%
2,244 $348,000
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $112,235 - $139,670
-847 Reduced 25.35%
2,494 $336,000
Q4 2022

Feb 08, 2023

SELL
$138.31 - $165.87 $138 - $165
-1 Reduced 0.03%
3,341 $540,000
Q3 2021

Nov 08, 2021

BUY
$106.4 - $120.78 $15,640 - $17,754
147 Added 4.6%
3,342 $361,000
Q1 2021

May 03, 2021

SELL
$102.3 - $112.62 $23,017 - $25,339
-225 Reduced 6.58%
3,195 $346,000
Q1 2020

Apr 27, 2020

SELL
$64.5 - $97.79 $16,125 - $24,447
-250 Reduced 6.81%
3,420 $261,000
Q3 2019

Nov 01, 2019

BUY
$62.98 - $75.72 $47,235 - $56,790
750 Added 25.68%
3,670 $278,000
Q2 2019

Aug 05, 2019

SELL
$65.7 - $83.98 $32,850 - $41,990
-500 Reduced 14.62%
2,920 $212,000
Q1 2018

Apr 25, 2018

SELL
$92.01 - $123.21 $9,201 - $12,321
-100 Reduced 2.84%
3,420 $324,000
Q4 2017

Jan 29, 2018

SELL
$89.56 - $98.21 $26,868 - $29,462
-300 Reduced 7.85%
3,520 $340,000
Q3 2017

Nov 02, 2017

BUY
$69.85 - $89.22 $266,827 - $340,820
3,820
3,820 $339,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Sonata Capital Group Inc Portfolio

Follow Sonata Capital Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sonata Capital Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Sonata Capital Group Inc with notifications on news.